PT  - JOURNAL ARTICLE
AU  - McDermott, Gregory C
AU  - Hayashi, Keigo
AU  - Yoshida, Kazuki
AU  - Moll, Matthew
AU  - Cho, Michael H
AU  - Doyle, Tracy J
AU  - Kinney, Gregory L
AU  - Dellaripa, Paul F
AU  - Putman, Rachel K
AU  - Jose Estepar, Raul San
AU  - Hata, Akinori
AU  - Hino, Takuya
AU  - Hida, Tomoyuki
AU  - Yanagawa, Masahiro
AU  - Nishino, Mizuki
AU  - Washko, George
AU  - Regan, Elizabeth
AU  - Hatabu, Hiroto
AU  - Hunninghake, Gary M
AU  - Silverman, Edwin K
AU  - Sparks, Jeffrey A
TI  - Prevalence and mortality associations of interstitial lung abnormalities in rheumatoid arthritis within a multicenter prospective cohort of smokers
AID  - 10.1101/2022.12.17.22283610
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.12.17.22283610
4099  - http://medrxiv.org/content/early/2022/12/18/2022.12.17.22283610.short
4100  - http://medrxiv.org/content/early/2022/12/18/2022.12.17.22283610.full
AB  - Objectives Investigate the prevalence and mortality impact of interstitial lung abnormalities (ILA) in rheumatoid arthritis (RA) and non-RA comparators.Methods We analyzed associations between ILA, RA, and mortality in COPDGene, a multicenter prospective cohort study of current or former smokers, excluding known interstitial lung disease (ILD) or bronchiectasis. All participants had research chest high-resolution computed tomography (HRCT) reviewed by a sequential reading method to classify ILA as present, indeterminate, or absent as well as fibrotic or nonfibrotic ILA subtype. RA cases were identified by self-report RA and DMARD use; non-RA comparators had neither an RA diagnosis nor used DMARDs. We examined the association and mortality risk of RA and ILA using multivariable logistic regression and Cox regression.Results We identified 83 RA cases and 8725 non-RA comparators with HRCT performed for research purposes. ILA prevalence was 16.9% in RA cases and 5.0% in non-RA comparators. After adjusting for potential confounders including genetics, smoking, and other lifestyle factors, ILA were more common among those with RA compared to non-RA (OR 4.76 95%CI 2.54 to 8.92). RA with ILA or indeterminate for ILA was associated with higher mortality compared to non-RA without ILA (HR 3.16, 95%CI 2.11 to 4.74) and RA cases without ILA (HR 3.02, 95%CI 1.36 to 6.75).Conclusions RA was associated with ILA and this persisted after adjustment for smoking and genetic/lifestyle risk factors. RA with ILA in chronic heavy smokers had 3-fold increased mortality, emphasizing the importance of further screening and treatment strategies for subclinical ILD in RA.What is already known on this topicUp to a third of patients with rheumatoid arthritis (RA) may have evidence of subclinical interstitial lung abnormalities on computed tomography (CT) scans of the chest.Cigarette smoking and the MUC5B promoter variant are known risk factors for RA-associated interstitial lung disease.What this study addsWe found that 17% of RA patients had subclinical interstitial lung abnormalities. RA had 4-fold higher odds of interstitial lung abnormalities than non-RA comparators, adjusted for smoking, the MUC5B promoter variant, and other factors.Participants with RA and no interstitial lung abnormalities were not at increased mortality risk while those with interstitial lung abnormalities or indeterminate for ILA had a three-fold increased risk of mortality compared to RA and non-RA patients without interstitial lung abnormalities.How this study might affect research, practice or policyThe presence of subclinical interstitial lung abnormalities confers significant mortality risk in RA and emphasizes the need to establish the clinical utility of screening, prevention, and treatment strategies targeting subclinical lung disease.Competing Interest StatementFunding: GCM is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant number T32 AR007530) and the VERITY Pilot & Feasibility Award. JAS is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant numbers R01 AR077607, P30 AR070253, and P30 AR072577), the R. Bruce and Joan M. Mickey Research Scholar Fund, and the Llura Gund Award for Rheumatoid Arthritis Research and Care. MHC was supported by R01HL153248, R01HL149861, R01HL147148. COPDGene was supported by Award Number U01 HL089897 and Award Number U01 HL089856 from the National Heart, Lung, and Blood Institute. COPDGene is also supported by the COPD Foundation through contributions made to an Industry Advisory Board that has included AstraZeneca, Bayer Pharmaceuticals, Boehringer-Ingelheim, Genentech, GlaxoSmithKline, Novartis, Pfizer, and Sunovion. The funders had no role in the decision to publish or in the preparation of this article. The content is solely the responsibility of the authors and does not necessarily represent the official views of Harvard University, its affiliated academic healthcare centres or the National Institutes of Health. YK reports consulting fees to OM1 unrelated to this work. MM reports institutional grant support from Bayer. TJD reports grant funding and other support from Bristol Myers Squibb and Genentech and personal fees from Boehringer Ingelheim and L.E.K. Consulting, unrelated to this study. PFD reports grant support from Genentech and Bristol Myers Squibb, royalties or licenses from Up To Date, Inc, and participation on a Federal Drug Administration advisory board. RSJE received grant support from Boehringer Ingelheim, and he is a confounder an equity holder of Quantitative Imaging Solutions. MN reports research grants from Canon Medical Systems, AstraZeneca, and Daiichi Sankyo and consulting fees from AstraZeneca and Daiichi Sankyo. HH reports grants or contracts and consulting fees from Canon Medical Systems, Inc. grants or contracts from Konica-Minolta, Inc. and consulting fees from Mitsubishi Chemical Company. GMH reports consulting fees from Boehringer-Ingelheim, the Gerson Lehrman Group, and Chugai Pharmaceuticals, unrelated to this work. EKS has received grant support from GSK and Bayer, unrelated to this work. MHC has received grant funding from GSK and Bayer, and speaking or consulting fees from AstraZeneca, Illumina, and Genentech, unrelated to this work. JAS has received research support from Bristol Myers Squibb and performed consultancy for AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Gilead, Inova Diagnostics, Janssen, Optum, and Pfizer unrelated to this work. Other authors report no competing interests.Funding StatementGCM is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant number T32 AR007530) and the VERITY Pilot & Feasibility Award. JAS is supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant numbers R01 AR077607, P30 AR070253, and P30 AR072577), the R. Bruce and Joan M. Mickey Research Scholar Fund, and the Llura Gund Award for Rheumatoid Arthritis Research and Care. MHC was supported by R01HL153248, R01HL149861, R01HL147148. COPDGene was supported by Award Number U01 HL089897 and Award Number U01 HL089856 from the National Heart, Lung, and Blood Institute. COPDGene is also supported by the COPD Foundation through contributions made to an Industry Advisory Board that has included AstraZeneca, Bayer Pharmaceuticals, Boehringer-Ingelheim, Genentech, GlaxoSmithKline, Novartis, Pfizer, and Sunovion.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Mass General Brigham Institutional Review Board, protocol number 2020P000558.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are available upon reasonable request and with appropriate institutional review board approval.